Objective  To analyze the application status of bioinformatics on Chinese medical graduate students.

Methods  Available academic thesis was filtered with a topic of bioinformatics medical research ranging from 2003 January 1st to 2023 December 31st in CNKI  and WanFang Database. The VOSviewer software was used to analyze the research hotspots of the academic thesis of Chinese medical graduate students, taking oncology as an example, the application status of bioinformatics in clinical practice was investigated.

Results  A total of 22,298 theses were included, comprising 14,036 master's theses (62.95%) and 8,262 doctoral theses (37.05%). In the last two decades, the number of bioinformatics-related thesis for Chinese medical student has been increasing continuously. The research hotspots of academic thesis mainly focused on expression analysis, mechanistic study, database and oncology. Notably, oncology-related research accounted for 45.72% of the theses. For lung cancer, application of bioinformatics has provided data support for pharmacological target investigation, diagnosis assistance and therapeutic effect monitoring in preclinical research. In addition, bioinformatics has been employed to aid clinical decision making, such as diagnosis and determination of therapeutic strategies.

Conclusion  The application of bioinformatics in the theses of medical postgraduates in China is increasing rapidly, particularly in the field of oncology. In clinical oncology practice, bioinformatics plays a pivotal role in early diagnosis, personalized therapy, and prognostic  evaluation.

1.王战军, 张微. 70年探索奋斗: 中国研究生教育发展规律与启示[J]. 学位与研究生教育, 2019, (9): 43-48. [Wang  ZJ, Zhang  W. 70 years exploration of the norm of graduate education in China[J]. Academic Degrees & Graduate Education, 2019, (9): 43-48.] DOI: 10.16750/j.adge.2019.09.008.

2.曲继鹏. 基于CNKI数据库的毕业设计教学文献分析[J]. 西昌学院学报(自然科学版), 2019, 33(3): 124-128. [Qu  JP. Analysis of graduation design teaching documents based on CNKI database[J]. Journal of Xichang University (Natural Science Edition), 2019, 33(3): 124-128.] DOI: 10.16104/j.issn.1673-1891.2019.03.029.

3.谢寒杰, 晋治波, 盖京苹. 我国微生物学相关方向研究生论文选题变化分析(1999—2018年)[J]. 微生物学通报, 2022, 49(8): 3539-3549. [Xie HJ, Jin ZB, Gai JP. Research topics in microbiology for graduate students in China (1999—2018)[J]. Microbiology China, 2022, 49(8): 3539-3549.] DOI: 10.13344/j.microbiol.china.211133.

4.Wang Z, Wu L, Li B, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)[J]. J Clin Oncol, 2023, 41(3): 651-663. DOI: 10.1200/jco.22.00727.

5.Chiappori AA, Creelan B, Tanvetyanon T, et al. Phase Ⅰ study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab (PDR001), in patients with advanced non-small cell lung cancer[J]. Clin Cancer Res, 2022, 28(11): 2313-2320. DOI: 10.1158/1078-0432.Ccr-21-2742.

6.Cooper AJ, Kobayashi Y, Kim D, et al. Identification of a ras-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26(15): 4072-4079. DOI: 10.1158/1078-0432.Ccr-20-0397.

7.Chaft JE, Oezkan F, Kris MG, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial[J]. Nat Med, 2022, 28(10): 2155-2161. DOI: 10.1038/s41591-022-01962-5.

8.Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451[J]. J Clin Oncol, 2021, 39(12): 1349-1359. DOI: 10.1200/jco.20.02212.

9.Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(12): 1655-1669. DOI: 10.1016/s1470-2045(19)30634-5.

10.Sullivan FM, Mair FS, Anderson W, et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging[J]. Eur Respir J, 2021, 57(1): 2000670. DOI: 10.1183/13993003.00670-2020.

11.Abbosh C, Frankell AM, Harrison T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA[J]. Nature, 2023, 616(7957): 553-562. DOI: 10.1038/s41586-023-05776-4.

12.周理韡, 郑书栋, 黄硕, 等. 生物信息学技术在生殖领域中的研究进展[J]. 国际生殖健康/计划生育杂志, 2022, 41(6): 487-493. [Zhou LW, Zheng SD, Huang S, et al Research progress of bioinformatics technology in reproductive system[J]. Journal of International Reproductive Health/Family Planning, 2022, 41(6): 487-493.] DOI: 10.12280/gjszjk.20220361.

13.李伟. 生物信息学分析对于肿瘤学硕士研究生培养的意义 [J]. 中国继续医学教育, 2023, 15(10): 170-173. [Li W. Significance of bioinformatics analysis for the training of postgraduates in oncology[J]. China Continuing Medical Education, 2023, 15(10): 170-173.] DOI: 10.3969/j.issn.1674-9308.2023.10.038.

14.中国抗癌协会肿瘤基因诊断专业委员会, 中国抗癌协会整合肿瘤学分会. 肿瘤基因诊断二代测序生物信息学分析平台本地化建设中国专家共识(2024年版)[J]. 中国癌症防治杂志, 2024, 16(6): 638-649. [Tumor Gene Diagnosis Committee of the China Anti-Cancer Association, Integrative Oncology Branch of the China Anti-Cancer Association. Chinese expert consensus on the localization of bioinformatics analysis for tumor genetic diagnosis using next-generation sequencing (2024 edition) [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 638-649.] DOI: 10.3969/j.issn.1674-5671.2024.06.02.

15.武文䶮. 生物信息学在生物医学领域的应用[J]. 学园, 2024, 17(23): 95-97. [Wu WY Applications of bioinformatics in the biomedical field [J]. Academy, 2024, 17(23): 95-97.] https://www.cnki.com.cn/Article/CJFDTotal-XYJK202423031.htm